(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/126087 A1

(51) International Patent Classification:
A61K 31/58 (2006.01) *A61K 31/53* (2006.01)
A61K 38/16 (2006.01) *A61P 25/08* (2006.01)

(21) International Application Number:
PCT/SG2020/050762

(22) International Filing Date:
18 December 2020 (18.12.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/949,603 18 December 2019 (18.12.2019) US

(71) Applicants: **NATIONAL UNIVERSITY OF SINGAPORE** [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). **SINGAPORE HEALTH SERVICES PTE LTD** [SG/SG]; 31 Third Hospital Avenue, Bowyer Block C, #13-03, Singapore 168753 (SG). **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: **JE, Hyunsoo Shawn**; c/o Duke-NUS Medical School, 8 College Road, Singapore 169857 (SG). **YUAN, Qiang**; c/o Duke-NUS Medical School, 8 College Road, Singapore 169857 (SG). **SUN, Xuyang**; c/o Singapore Health Services PTE Ltd, 31 Third Hospital Avenue, Bowyer Block C, #13-03, Singapore 168753 (SG).

(74) Agent: **DOWSING, Bruce John**; Marks & Clerk Singapore LLP, Tanjong Pagar Post Office, P O Box 636, Singapore 910816 (SG).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: METHOD FOR TREATING ANGELMAN SYNDROME AND RELATED DISORDERS

Fig. 4B



(57) Abstract: The present invention relates to methods of treating or ameliorating seizures relating to disruptions in Ubiquitin Protein Ligase E3A (UBE3A) gene. More particularly, the invention relates to the use of BK channel antagonists for the prophylaxis or treatment of seizures in a subject with Angelman syndrome or related autism spectrum disorder (ASD). In some embodiments, BK channel antagonist is Paxilline, iberiotoxin (IBTX) or GAL-021.

WO 2021/126087 A1